Rheumatoid Arthritis, Gout, Osteoarthritis
Conditions
Keywords
Rheumatoid arthritis, Dendritics cells
Brief summary
First, this study will evaluate, in vitro, the cellular composition of the synovial fluid from patient with rheumatoid arthritis, gout or osteoarthritis. Then samples will be test with a new format of bispecific antibody targeting dendritic cells. The production of IL-10 will be the principal criteria of judgment. Production of others cytokines like IL-1B, IL-6, IL-12 and IFN will be checked as well.
Detailed description
Rheumatoid arthritis (RA) is one of the most common autoimmune disease in adult. It exists several drugs but none target dendritic cells even if it seems they play a major role in the physiopathology. One of the unit of research of Tours recently develop a new format of bispecific antibody which target dendritic cells. The first results in PBMC (unpublished yet) show an increase of the production of IL-10 In this study, we are going to first evaluate the cellular composition of synovial fluid from patients with RA and patients with gout (for the comparison, because the inflammatory mechanisms are different) and with osteoarthritis (comparison with a non inflammatory disease) Then, we will use this new antibody and evaluate the response by dosing Il-10, IL-6, IL-12, IL1B and IFNy The aim is to verify in vitro if, with this new drug, it is possible to reverse the inflammation and induce a tolerance.
Interventions
OTHERPuncture
Puncture necessary for daily practice in patients with acute arthritis of RA or Gout or osteoarthritis
Sponsors
University Hospital, Tours
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female over 18 years old * Proven and possible RA or Gout or osteoarthritis * Arthritis accessible to a puncture * Necessary puncture for diagnosis or therapeutic
Exclusion criteria
* Microcrystalline rheumatism other than Gout * Known SpA * Septic arthritis * Biomedicament treatment * Patient having objected to the processing of his data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Production of IL-10 | 48 hours | Evaluate the production of IL-10 by cells from synovial fluid after the use of a new antibody format |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Production of Il-6 | 48 hours | Evaluate the production of IL-6 by cells from synovial fluid after the use of a new antibody format |
| Production of IFN | 48 hours | Evaluate the production of IFN by cells from synovial fluid after the use of a new antibody format |
| Production of IL1B | 48 hours | Evaluate the production of IL1B by cells from synovial fluid after the use of a new antibody format |
| Production of IL12 | 48 hours | Evaluate the production of IL12 by cells from synovial fluid after the use of a new antibody format |
Countries
France
Outcome results
None listed